drugset / Trial / NCT04388189

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

NCT04388189

Phase 4 Withdrawn Alto Neuroscience
RandomizedParallel-groupOpen-labelTreatment

Summary

The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.

Timeline

Start
2020-10-15
Primary completion
2023-05-30
Completion
2023-05-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule 150 mg
Comparator Bupropion Small molecule 450 mg
Subject Duloxetine Small molecule 60 mg